Amaravati seed capital road

Engine Biosciences Secures $27 Million Series A Extension to Advance Development of Precision Oncology Medicines and Novel Biomarkers for Patient Selection

Retrieved on: 
星期二, 十月 31, 2023
Biotechnology, Professional Services, Health, General Health, Pharmaceutical, Oncology, Health Technology, Research, Genetics, Science, Finance, Neoplasm, Polaris Partners, MIT, Enterprise Singapore, UCSF, Silicon, Biomarker, Therapy, Economics, UCSD, Liver, Amaravati seed capital road, INVU (song), Drug development, Enterprise, Temasek, Lung, Growth, PKMYT1, Medicine, Biology, Machine learning, SEEDS, Doctor of Philosophy, Mayo Clinic, Medical imaging, Pharmaceutical industry, Engine

Engine Biosciences , a company leveraging machine learning and high-throughput biology to discover and develop precision oncology medicines, today announced the completion of a $27 million Series A extension.

Key Points: 
  • Engine Biosciences , a company leveraging machine learning and high-throughput biology to discover and develop precision oncology medicines, today announced the completion of a $27 million Series A extension.
  • Engine’s precision medicine R&D platform deciphers biological networks and pinpoints key genetic interactions driving diseases, overcoming challenges presented by biological complexity.
  • These insights reveal targets and therapeutics to be used in biomarker-defined patient populations, allowing for more rapid identification of effective precision medicines.
  • In addition to high-value targets and drug candidates, Engine identified new patient selection biomarkers for several distinct classes of targeted therapies.

Aktivolabs Earns HIPAA Certification and Launches Operations in the United States

Retrieved on: 
星期五, 十月 6, 2023
Technology, Insurance, Health Technology, Professional Services, Data Analytics, General Health, Health, Data Management, Science, Other Science, Dai, Prediabetes, AXA, Certification, GDPR, Dai-ichi, DPA, Risk, HIPAA, SEEDS, Digital, Amaravati seed capital road, Diabetes, ISO, Mitsui, Type, PDPA, Sleep, Digital health, CBT, ISO 27001, Privacy, Life, Enterprise Singapore, Conditional sentence, Cryptocurrency, Sun Life Financial

Aktivolabs, a digital health science company, announced today HIPAA compliance and the launch of its operations in the United States.

Key Points: 
  • Aktivolabs, a digital health science company, announced today HIPAA compliance and the launch of its operations in the United States.
  • “HIPAA, for Aktivolabs, is a validation and testament to our unwavering commitment to upholding the highest standards of data security and privacy,” says Gourab Mukherjee, Co-founder, and CEO of Aktivolabs.
  • Aktivolabs has over half a million paid subscribers, and global clients and partners include Marsh Mercer, AXA, Sunlife, and Dai-ichi.
  • “We respond to this spending challenge with our expansion to the US and recent HIPAA certification to be a trusted partner in the US.

Albatroz Therapeutics Secures $3 Million to Develop First-Ever Therapy Blocking a Universal Process Involved in the Growth and Spread of Cancerous Solid Tumors and Arthritic Cartilage Degradation

Retrieved on: 
星期二, 四月 25, 2023
Research, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Oncology, Acceleration, Joint capsule, GALA, Amaravati seed capital road, IMCB, Agency for Science, Technology and Research, Arthritis, Institute of Molecular and Cell Biology, Neoplasm, SEEDS, Connective tissue, Biologic, The Golden Ticket, Toxicity, Antibody, Albatroz-class patrol boat, Duke–NUS Medical School, Cell biology, Patient, Extracellular matrix, Golden Ticket, CSCB, Growth, Therapy, Recurrence, Glycosylation, Metastasis, Pharmaceutical industry, Vaccine, Amgen, Cancer

The company also received the first Golden Ticket prize from Amgen in Singapore, recognizing the viability of its science and business plan.

Key Points: 
  • The company also received the first Golden Ticket prize from Amgen in Singapore, recognizing the viability of its science and business plan.
  • Cancer that has metastasized, spreading to other parts of the body, is notoriously difficult to treat and accounts for most cancer deaths.
  • Albatroz has secured exclusive rights on a highly specific and novel target that blocks tumor growth and recurrence, including a range of therapeutic antibodies that inhibit this target.
  • Activation of the target occurs specifically in tumors and arthritic synovial membranes, connective tissue that lines the joint capsule.

SepPure Technologies Closes Series-A Funding Round, Raises US$12M

Retrieved on: 
星期二, 二月 28, 2023
Solvent, Climate, Amaravati seed capital road, PH, MIT, EPS, Global warming potential, Distillation, Burn, SOSV, HAX, Sewage treatment, Renewable energy

SepPure Technologies has developed a highly sustainable, chemical-resistant, nanofiltration solution that separates chemical mixtures at a molecular level with minimal energy usage.

Key Points: 
  • SepPure Technologies has developed a highly sustainable, chemical-resistant, nanofiltration solution that separates chemical mixtures at a molecular level with minimal energy usage.
  • SepPure's nanofiltration technology uses pressure-driven filtration instead of heat, which reduces energy consumption by 90%.
  • The filter technology is applicable across a wide range of industries, including chemicals, pharmaceuticals, semiconductor, maritime, and plant-based oils.
  • In fact, these technologies have become one of the world's largest silent polluters, accounting for up to 15% of the planet's entire energy consumption.

Accelerating Energy Efficiency Adoption, Deep-tech Startup KrossLinker Develops a Cost-effective Aerogel Insulation

Retrieved on: 
星期四, 二月 2, 2023
Vaccine, Hospital, ADB, Amaravati seed capital road, Clinical trial, Research, Third derivative, Temperature, Vehicle registration plates of Nepal, Entrepreneur First, Enterprise Singapore, Renewable energy

KrossLinker's first aerogel product, Cryar® Aerogel Board, targets the cold-chain industry, where a positive market growth trend is expected.

Key Points: 
  • KrossLinker's first aerogel product, Cryar® Aerogel Board, targets the cold-chain industry, where a positive market growth trend is expected.
  • A 2020 report indicated that packaging costs account for around 30% of the total spending of pharmaceutical cold chain companies.
  • KrossLinker has collaborated with several specialty packaging, logistic companies, and hospitals to commercialize and accelerate the adoption of Cryar® aerogel shippers.
  • With faster production and low energy consumption of the novel drying technology, our aerogel is made at half the production and capital expenditure of traditional aerogel without compromising its performance.

ION Mobility Closes US$18.7m in Series A funding; Brings TVS Motor Company on Board as Strategic Investor

Retrieved on: 
星期五, 二月 3, 2023
Mobius, Marketing, ION, Perusahaan Listrik Negara, MOU, Seed, Education, Ecosystem, EV, Spectrometry, TVS Motor Company, Ion-mobility spectrometry, Moebius, Memorandum of understanding, PLN, Partnership, Quest Ventures, Investment, Amaravati seed capital road, Research, Mobile phone

Additionally, the company also brings TVS Motor Company on board as its strategic investor, through TVS Motor's Singapore subsidiary, TVS Motor (Singapore).

Key Points: 
  • Additionally, the company also brings TVS Motor Company on board as its strategic investor, through TVS Motor's Singapore subsidiary, TVS Motor (Singapore).
  • As part of this investment agreement, TVS Motor will provide ION with the necessary ecosystem support to be successful in the electric two-wheeler markets of Singapore and Indonesia.
  • ION's latest fundraise and partnership with TVS Motor is to support its vision to build Southeast Asia's leading electric mobility solutions company starting with Indonesia.
  • Speaking on the occasion, Mr. Sudarshan Venu, Manging Director, TVS Motor Company said, "TVS Motor is committed to developing exciting products for consumers across global markets.

X0PA AI RAISES $4.2 MILLION IN SERIES A FUNDING TO SCALE AI-POWERED OBJECTIVE B2B HIRING & SELECTIONS SOLUTION

Retrieved on: 
星期二, 一月 4, 2022
SBI Group, Time, Investment, ICCP, Intel, AI, Artificial intelligence, Acquisition, RPA, Government, ROI, Amaravati seed capital road, Growth, APAC, Big data, Silicon, Partner, SAP, Enterprise Singapore, History, VC, SEEDS, Software as a service, General manager, Algorithm, Machine learning, CEO, The Future of Work and Death, Bias, ML, Automation, Len Bias, Partnership, Subjectivity, Technology, Pressure, IDC, Solution, Microsoft Azure, Multimedia, Robotic process automation, Microsoft, Equitable, Management, Medical device, Airline, Video game, Nvidia, Oracle

SINGAPORE, Jan. 4,2022 /PRNewswire/ -- X0PA AI , a leader in AI-powered objective hiring solutions, today announced $4.2 million USD in Series A funding.

Key Points: 
  • SINGAPORE, Jan. 4,2022 /PRNewswire/ -- X0PA AI , a leader in AI-powered objective hiring solutions, today announced $4.2 million USD in Series A funding.
  • The new funding comes on the back of significant growth into new markets and the launch of trailblazing inclusive hiring innovations.
  • X0PA is solving the talent bottleneck by utilizing AI to find highly talented outliers that do not necessarily fit regular profiles.
  • To learn more about X0PA AI and find out how you can maximise objective hiring and reduce your time and cost to hire, please visit www.x0pa.com .

X0PA AI RAISES $4.2 MILLION IN SERIES A FUNDING TO SCALE AI-POWERED OBJECTIVE B2B HIRING & SELECTIONS SOLUTION

Retrieved on: 
星期二, 一月 4, 2022
SBI Group, Time, Investment, ICCP, Intel, AI, Artificial intelligence, Acquisition, RPA, Government, ROI, Amaravati seed capital road, Growth, APAC, Big data, Silicon, Partner, SAP, Enterprise Singapore, History, VC, SEEDS, Software as a service, General manager, Algorithm, Machine learning, CEO, The Future of Work and Death, Bias, ML, Automation, Len Bias, Partnership, Subjectivity, Technology, Pressure, IDC, Solution, Microsoft Azure, Robotic process automation, Microsoft, Equitable, Management, Medical device, Airline, Video game, Nvidia, Oracle

SINGAPORE, Jan. 4, 2022 /PRNewswire/ -- X0PA AI, a leader in AI-powered objective hiring solutions, today announced $4.2 million USD in Series A funding. The investment was led by ICCP SBI Venture Partners (ISVP), with additional funding from SEEDS Capital, AI8 Ventures, XCEL NEXT VENTURES, and SASV Investments. The new funding comes on the back of significant growth into new markets and the launch of trailblazing inclusive hiring innovations.

Key Points: 
  • SINGAPORE, Jan. 4,2022 /PRNewswire/ -- X0PA AI , a leader in AI-powered objective hiring solutions, today announced $4.2 million USD in Series A funding.
  • The new funding comes on the back of significant growth into new markets and the launch of trailblazing inclusive hiring innovations.
  • X0PA is solving the talent bottleneck by utilizing AI to find highly talented outliers that do not necessarily fit regular profiles.
  • To learn more about X0PA AI and find out how you can maximise objective hiring and reduce your time and cost to hire, please visit www.x0pa.com .